# NCT06200233 (NCT06200233)

> Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06200233
- Phase: PHASE2
- Status: NOT_YET_RECRUITING
- Sponsor: Samsung Medical Center
- Conditions: Thymic Epithelial Tumor
- Interventions: Rivoceranib
- Enrollment: 40
- Primary outcome: Objective response rate(ORR) Objective response rate(ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06200233